Skip to main content
Caris Life Sciences8-K: Material contract

Caris Life Sciences secures up to $1.2B in new financing, with $300M earmarked for acquisitions.

What happened

The company has secured a significant capital infusion, including a $400M initial loan and a $300M facility explicitly for M&A.

Source

SEC EDGARApr 2, 2026

Current report (Form 8-K)

Caris Life Sciences 8-K

Filing excerpt

The New Credit Agreement provides for certain senior secured credit facilities to the Company consisting of (a) an initial term loan in an aggregate principal amount equal to $400,000,000, funded on the Closing Date (the “Initial Term Facility”), (b) a committed delayed draw term loan facility in an aggregate principal amount that may be drawn in one or more tranches not to exceed $300,000,000 in the aggregate (“Delayed Draw Facility”), and (c) an uncommitted incremental facility in an aggregate principal amount not to exceed $500,000,000.

sec.gov/Archives/edgar/data/2019410/000201941026000019/cai-20260401.htmRead the full source

Other signals in this filing (2)

Extracted by Autobound

From the Signal API record
Signal
8-K: Material contract

What this signalsFilings often name leadership changes, deals and spending plans.

Form
8-K
Fiscal year end
04/01
Filed
Apr 2, 2026

The full record

From the Signal API record

Numbers

Dollar figure
$700M (Committed new credit facilities, including a $400M initial term loan and a $300M delayed draw facility for acquisitions. An additional $500M is available in...)

Details

CIK
2019410
Accession number
0002019410-26-000019
Timeframe
Current quarter
Filing year
2026
Why it matters
Vendor relationship signal
Signal category
Strategic

Topics and mentions

Vendors

  • Blue Owl Capital
  • Blackstone
  • Wilmington Trust
  • National Association

Vendors named

  • Blue Owl Capital
  • Blackstone
  • Wilmington Trust, National Association

Extraction

Confidence
High
Relevance
90%
Sentiment
Positive
Detected
Apr 7, 2026
signal_type
sec-8k
signal_subtype
materialContract

Use this data

Get every 8-K signal for Caris Life Sciences and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Caris Life Sciences this week?”

  2. Send it to your own tools

    The Signal API returns 8-K signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full sec-8k record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/8eaf5297-e568-4e58-8e75-7971e1e9cc3a returns this record as JSON. POST /v1/companies/enrich returns every signal for carislifesciences.com.

{
  "signal_id": "8eaf5297-e568-4e58-8e75-7971e1e9cc3a",
  "signal_type": "sec-8k",
  "signal_subtype": "materialContract",
  "detected_at": "2026-04-07T09:30:39.623+00:00",
  "company": {
    "name": "Caris Life Sciences",
    "domain": "carislifesciences.com"
  },
  "data": {
    "detail": "The company has secured a significant capital infusion, including a $400M initial loan and a $300M facility explicitly for M&A. This creates immediate opportunities for vendors supporting acquisition integration, due diligence, and rapid scaling of operations.",
    "metrics": {
      "timeframe": "current_quarter",
      "dollar_context": "Committed new credit facilities, including a $400M initial term loan and a $300M delayed draw facility for acquisitions. An additional $500M is available in an uncommitted facility.",
      "dollar_millions": 700
    },
    "summary": "Caris Life Sciences secures up to $1.2B in new financing, with $300M earmarked for acquisitions.",
    "excerpts": "The New Credit Agreement provides for certain senior secured credit facilities to the Company consisting of (a) an initial term loan in an aggregate principal amount equal to $400,000,000, funded on the Closing Date (the “Initial Term Facility”), (b) a committed delayed draw term loan facility in an aggregate principal amount that may be drawn in one or more tranches not to exceed $300,000,000 in the aggregate (“Delayed Draw Facility”), and (c) an uncommitted incremental facility in an aggregate principal amount not to exceed $500,000,000.",
    "relevance": 0.9,
    "sentiment": "positive",
    "confidence": "high",
    "source_url": "https://www.sec.gov/Archives/edgar/data/2019410/000201941026000019/cai-20260401.htm",
    "filing_date": "2026-04-02",
    "filing_year": 2026,
    "fiscal_year_end": "04/01",
    "sales_relevance": "Vendor relationship signal",
    "signal_category": "strategic",
    "vendors_mentioned": [
      "Blue Owl Capital",
      "Blackstone",
      "Wilmington Trust, National Association"
    ]
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.